文献速递间质性肺疾病

抗原暴露对纤维化性过敏性肺炎结局与治疗反应的影响

Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis.
PubMed 文献 · Chest · 2023-12-19

本研究基于加拿大肺纤维化注册数据库,纳入344例纤维化性过敏性肺炎患者,按致病抗原分为鸟类、霉菌、其他和未知四组。

要点

  • 纤维化性过敏性肺炎患者中未知抗原占43%,鸟类占27%,霉菌占26%。
  • 全队列中免疫抑制治疗未改善肺功能或症状评分。
  • 未知抗原患者接受免疫抑制治疗与更差生存相关(HR 2.65)。

核心结论

  • 纤维化性过敏性肺炎患者对免疫抑制治疗的反应因抗原类型而异。
  • 未知抗原患者接受免疫抑制治疗与更差生存相关。

研究设计与样本

  • 多中心间质性肺疾病数据库(加拿大肺纤维化注册)回顾性识别纤维化性过敏性肺炎患者。
  • 共纳入344例患者,按致病抗原分为鸟类(n=93;27%)、霉菌(n=88;26%)、其他(n=15;4%)和未知(n=148;43%)四组。
  • 免疫抑制治疗定义为霉酚酸酯≥1000 mg/d或硫唑嘌呤≥75 mg/d持续≥30天。
  • 统计分析包括t检验、χ2检验、单因素方差分析,以及未调整和调整的竞争风险和Cox比例风险模型评估生存。

主要发现

  • 各组患者特征和肺功能相似,平均FVC%预测值为75±20。
  • 58%的患者接受免疫抑制治疗,各抗原组间治疗比例相似。
  • 全队列中启动免疫抑制治疗后肺功能或症状评分无变化。

关键数值与推荐

  • 免疫抑制治疗定义:霉酚酸酯≥1000 mg/d或硫唑嘌呤≥75 mg/d持续≥30天。
  • 全队列平均FVC%预测值:75±20。

临床怎么用

  • 对纤维化性过敏性肺炎患者启动免疫抑制治疗前应明确致病抗原类型。
  • 未知抗原患者使用免疫抑制治疗需谨慎评估风险与获益。
  • 鸟类或霉菌抗原患者免疫抑制治疗与生存无显著关联,需个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with fibrotic hypersensitivity pneumonitis (fHP) are frequently treated with immunosuppression to slow lung function decline; however, the impact of this treatment has not been studied across different types of antigen exposure. RESEARCH QUESTION: In patients with fHP, do disease outcomes and response to treatment vary by antigen type? STUDY DESIGN AND METHODS: A multicenter interstitial lung disease database (Canadian Registry for Pulmonary Fibrosis) was used to identify patients with fHP. The causative antigen was categorized as avian, mold, unknown, or other. Treatment was defined as mycophenolate ≥ 1,000 mg/d or azathioprine ≥ 75 mg/d for ≥ 30 days. Statistical analysis included t tests, χ2 tests, and one-way analysis of variance. Unadjusted and adjusted competing risks and Cox proportional hazards models were used to assess survival. RESULTS: A total of 344 patients were identified with the following causative antigens: avian (n = 93; 27%), mold (n = 88; 26%), other (n = 15; 4%), and unknown (n = 148; 43%). Patient characteristics and lung function were similar among antigen groups with a mean FVC % predicted of 75 ± 20. The percent of patients treated with immunosuppression was similar between antigens with 58% of patients treated. There was no change in lung function or symptom scores with the initiation of immunosuppression in the full cohort. Immunosuppression was not associated with a change in survival for patients with avian or mold antigen (avian: hazard ratio, 0.41; 95% CI, 0.11-1.59; P = .20; mold: hazard ratio, 1.13; 95% CI, 0.26-4.97; P = .88). For patients with unknown causative antigen, survival was worse when treated with immunosuppression (hazard ratio, 2.65; 95% CI, 1.01-6.92; P = .047). INTERPRETATION: Response to immunosuppression varies by antigen type in patients with fHP. Additional studies are needed to test the role of immunosuppression in fHP, and particularly in those with an unknown antigen.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Mullin ML, Fernandez G, Marinescu DC, et al. Impact of Antigen Exposure on Outcomes and Treatment Response in Fibrotic Hypersensitivity Pneumonitis. Chest. 2023. PMID: 38128609. doi:10.1016/j.chest.2023.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。